Patent Application for Agonistic TNF Receptor Binding Agents

The USPTO has published a new patent application, US20260085126A1, for agonistic TNF receptor binding agents. The application, filed on August 27, 2025, by inventors including Ugur Sahin, details binding agents for TNF superfamily receptors and their potential medical uses.

Patent Application for Apelin Receptor Binding Polypeptides and Methods

The USPTO has published a new patent application (US20260085125A1) for apelin receptor binding polypeptides and methods of treatment. The application was filed on November 25, 2025, and details antibodies and polypeptides that specifically bind to the apelin receptor (APJ).

Patent Application for Tenosynovial Giant Cell Tumor Treatment

The USPTO has published a patent application (US20260085124A1) detailing compositions and methods for treating tenosynovial giant cell tumor using intra-articular delivery of anti-CSF1R antibodies. The application, filed by Kirk William Johnson, focuses on sustained drug exposure within joints.

Patent Application: Anti-FGFR2 Antibodies with Chemotherapy for Cancer Treatment

The USPTO has published patent application US20260085123A1, filed by Five Prime Therapeutics, Inc. The application details the use of anti-FGFR2 antibodies in combination with mFOLFOX6 chemotherapy for treating certain cancers.

Patent Application: Antibodies Binding Human 4Ig-B7H3

The USPTO has published a new patent application (US20260085122A1) filed by BeOne Medicines I GmbH. The application relates to antibodies or antigen-binding fragments thereof that bind to human 4Ig-B7H3.

Patent Application: Multispecific Binding Constructs Against Checkpoint Molecules

The USPTO has published a new patent application (US20260085121A1) from Compass Therapeutics, LLC, detailing multispecific binding constructs against checkpoint molecules. The application focuses on compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression, specifically blocking interactions between PD-1 and its ligand.

All-in-one Agonistic Antibodies Patent Application

The USPTO has published a patent application (US20260085113A1) filed by Hoffmann-La Roche Inc. on October 2, 2025. The application describes antigen binding molecules comprising biparatopic target-binding domains and cytokine receptor-binding domains designed to selectively activate cytokine receptors.

Patent Application for Free LIGHT Detection and Treatment

The USPTO has published a patent application (US20260085112A1) from Avalo Therapeutics, Inc. for methods of detecting and treating conditions associated with elevated free LIGHT using anti-LIGHT antibodies. The application covers methods for diagnosing conditions like acute lung injury, ARDS, and Crohn's Disease.

Patent Application for SLIT2 Related Compositions and Methods

The USPTO has published a new patent application (US20260085111A1) filed by EVEREST MEDICINES (SINGAPORE) PTE. LTD. The application relates to antibodies that bind to SLIT2 and related substitution mutants, including their manufacture and use.

Patent Application: Production Method for Product to Prevent Membrane Clogging

The USPTO has published a patent application from FUJIFILM Corporation detailing a production method for a product that aims to prevent membrane clogging during cell culture. The method involves specific mathematical expressions related to poloxamer concentration, product concentration, and hydrophobicity index to optimize the cell culture process.